Lavelle Erin 4

What Happened

• Erin Lavelle, a director of Jade Biosciences (JBIO), was granted a derivative award (stock option) for 34,843 shares on June 9, 2026. The grant is reported as an acquisition (code A) with a reported price of $0.00—this is an option award, not an immediate sale or cash purchase.

Key Details

• Transaction date: 2026-06-09 (Filed on 2026-06-11)
• Transaction type/code: Grant/Award of a derivative security (option) — code A
• Amount: 34,843 shares (option to purchase common stock)
• Reported price: $0.00 (standard for option grants; no cash exchanged for shares now)
• Vesting: Vests in full on the earlier of (i) June 9, 2027 or (ii) the next annual meeting of stockholders, subject to Lavelle’s continued service (footnote F1).
• Shares owned after transaction: Not specified in the filing.
• Timeliness: Filing appears timely (reported within the standard Form 4 reporting window).

Context

• This was an option grant (a compensation award) rather than an outright purchase; the options must vest before they can be exercised into shares. Such grants are common as director compensation and do not by themselves indicate buying or selling sentiment.